Abstract | SUMMARY: INTRODUCTION: METHODS: In 131 postmenopausal females screened for participation in an osteoporosis trial, the 25-hydroxyvitamin D3 concentration was < 60 nmol/L. They were treated with 25 (n = 22), 50 (n = 19), 75 (n = 19), 100 (n = 41) or 200 microg ( n = 30) of vitamin D3 daily for at least 10 days. RESULTS: In the females treated with 25, 50, 75, 100 and 200 microg of vitamin D3 daily the 25-hydroxyvitamin D3 concentrations increased significantly from 32.4 +/- 2.7 (mean +/- SEM) to 50.8 +/- 2.9, from 46.7 +/- 2.8 to 65.8 +/- 2.6, from 41.6 +/- 2.7 to 67.4 +/- 2.9, from 46.7 +/- 1.4 to 64.4 +/- 2.2 and from 42.1 +/- 2.0 to 71.2 +/- 2.8 nmol/L, respectively (p < 0.001). S- calcium increased significantly but within the reference range (p < 0.006). CONCLUSION:
|
Authors | H C Hoeck, B Li, P Qvist |
Journal | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
(Osteoporos Int)
Vol. 20
Issue 8
Pg. 1329-35
(Aug 2009)
ISSN: 1433-2965 [Electronic] England |
PMID | 19083075
(Publication Type: Controlled Clinical Trial, Journal Article, Multicenter Study)
|
Chemical References |
- Bone Density Conservation Agents
- Cholecalciferol
- Calcifediol
|
Topics |
- Administration, Oral
- Aged
- Bone Density Conservation Agents
(administration & dosage, therapeutic use)
- Calcifediol
(blood, deficiency)
- Cholecalciferol
(administration & dosage, therapeutic use)
- Dietary Supplements
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Middle Aged
- Osteoporosis, Postmenopausal
(blood, drug therapy)
|